Improvement of diabetic retinopathy with intravitreal Ranibizumab

Marcus Kernt; Sarah Cserhati; Florian Seidensticker; Raffael Liegl; Anselm Kampik; Aljoscha Neubauer; Michael W Ulbig; Lukas Reznicek

doi:10.1016/j.diabres.2013.01.006

Improvement of diabetic retinopathy with intravitreal Ranibizumab

Diabetes Res Clin Pract. 2013 Apr;100(1):e11-3. doi: 10.1016/j.diabres.2013.01.006. Epub 2013 Feb 5.

Authors

Marcus Kernt¹, Sarah Cserhati, Florian Seidensticker, Raffael Liegl, Anselm Kampik, Aljoscha Neubauer, Michael W Ulbig, Lukas Reznicek

Affiliation

¹ Department of Ophthalmology, Ludwig-Maximilians-Universiy, Munich, Germany. marcus.kernt@med.uni-muenchen.de

PMID: 23391744
DOI: 10.1016/j.diabres.2013.01.006

Abstract

This study indicates that in addition to the significant improvement in visual acuity and reduction of central retinal thickness in patients with center-involving diabetic macular edema, intravitreal anti-VEGF treatment with Ranibizumab may also lead to a significant stabilization or even improvement of diabetic retinopathy.

MeSH terms

Angiogenesis Inhibitors / therapeutic use*
Antibodies, Monoclonal, Humanized / therapeutic use*
Diabetes Mellitus, Type 1 / complications*
Diabetes Mellitus, Type 1 / physiopathology
Diabetes Mellitus, Type 2 / complications*
Diabetes Mellitus, Type 2 / physiopathology
Diabetic Retinopathy / drug therapy*
Diabetic Retinopathy / physiopathology
Female
Fluorescein Angiography / methods
Follow-Up Studies
Humans
Intravitreal Injections
Macular Edema / drug therapy*
Macular Edema / etiology
Macular Edema / physiopathology
Male
Ranibizumab
Tomography, Optical Coherence / methods
Treatment Outcome
Vascular Endothelial Growth Factor A / antagonists & inhibitors*
Visual Acuity

Substances

Angiogenesis Inhibitors
Antibodies, Monoclonal, Humanized
VEGFA protein, human
Vascular Endothelial Growth Factor A
Ranibizumab